Nada Hamad
St. Vincent's Health System
Internal medicineSurgeryOncologyUnivariate analysisImmunologyHazard ratioHematopoietic stem cell transplantationDiffuse large B-cell lymphomaProgressive diseaseAlemtuzumabLymphomaGraft-versus-host diseasePopulationTransplantationCoronavirus disease 2019 (COVID-19)Incidence (epidemiology)MedicineCumulative incidenceGastroenterology
70Publications
9H-index
276Citations
Publications 75
Newest
#1Duncan Purtill (Fiona Stanley Hospital)H-Index: 8
#2Cheryl Hutchins (Royal Brisbane and Women's Hospital)H-Index: 8
Last. Karieshma Kabani (RPA: Royal Prince Alfred Hospital)H-Index: 6
view all 23 authors...
Abstract null null Background null Changes to donor availability, collection centre capacity and travel restrictions during the early phase of the COVID-19 pandemic led to routine cryopreservation of most unrelated donor products for haematopoietic transplantation prior to the recipient commencing the conditioning regimen. null null null Objective null We investigated the effect of this change on unrelated donor product quality and clinical outcomes. null null null Study Design null Product info...
Source
#1Joel WightH-Index: 7
#2Nada Hamad (USYD: University of Sydney)H-Index: 9
Last. Sze Ting LeeH-Index: 21
view all 13 authors...
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there rema...
Source
#1Jacinta Perram (UNSW: University of New South Wales)
#2Nada Hamad (UNSW: University of New South Wales)H-Index: 9
Source
#1Dietger Niederwieser (Lithuanian University of Health Sciences)
#2Helen Baldomero (University Hospital of Basel)H-Index: 42
Last. Nada Hamad (St. Vincent's Health System)H-Index: 9
view all 36 authors...
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission of promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries and individual centers. In 2016, 82,718 first HCTs were reported from 1662 HCT teams in 86 of the 195 World Health Organization member states representing a global increase of 6.2% in autologous and 7.0% in allogeneic HCT and bringing the total to 1,298,897 procedures. Assumin...
Source
#1Chandini Raina MacIntyre (UNSW: University of New South Wales)H-Index: 22
Last. Noor Bari
view all 5 authors...
The AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine is associated with Thrombosis with Thrombocytopenia Syndrome (TTS) in 3/100,000 vaccinations with high fatality rates reported in many countries. We conducted a risk-benefit analysis for Australians aged 18-59 years, comparing the risk of vaccination versus infection, and rate of TTS to other vaccines which prompted policy change following rare adverse events - rotavirus, smallpox and oral polio vaccines. COVID-19 deaths over 12 months range from...
1 CitationsSource
#1Nada Hamad (UNSW: University of New South Wales)H-Index: 9
Last. Matthew Greenwood (RNSH: Royal North Shore Hospital)H-Index: 8
view all 0 authors...
Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-1...
Source
#1René-Olivier Casasnovas (French Institute of Health and Medical Research)H-Index: 9
#2George A FollowsH-Index: 31
Last. Federica Cavallo (UNITO: University of Turin)H-Index: 63
view all 33 authors...
Abstract null null Background null The SADAL study evaluated oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor. null null null Patients and Methods null Data from 134 patients in SADAL were analyzed by DLBCL subtypes for overall response...
Source
Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9.3 months. The analyses described here evaluated a number of subpopulations in order to understand how response correlates with survival outcomes in order to identify patient...
Source
#1Catherine Tang (Wellington Management Company)H-Index: 1
#2Nada Hamad (UNSW: University of New South Wales)H-Index: 9
Source
#1Michael Scordo (Cornell University)H-Index: 14
#2Trent P Wang (UM: University of Miami)H-Index: 3
Last. Craig S. Sauter (Cornell University)H-Index: 30
view all 39 authors...
Importance Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. Objective To assess the outcomes in patients with PCNSL undergoing AHCT with the 3 most commonly used conditioning regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmus...
3 CitationsSource